| Name | Title | Contact Details |
|---|---|---|
Brian Riley |
Senior Vice President of Technical Operations | Profile |
Brad Dutot |
Vice President, Information Technology | Profile |
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Adamis Laboratories, Inc is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WN Pharmaceuticals Ltd is a Coquitlam, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leader in the manufacture of generic drugs, we produce and distribute brand name drugs and over-the-counter drugs. Based in Montreal, Canada, we have about 1 500 employees. Our products are sold in more than sixty countries. Our portfolio of 340 products cumulates 2000 different dosage strengths. We invest $ 30 million per year in research and development. We firmly believe that we must be an example in our community. We support many charities, here as elsewhere. For international humanitarian purposes, we have donated products valued at approximately $ 23.5 million over the past five years.
Kyowa Hakko Kirin Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.